Pharma stocks were trading firmly in the green on Tuesday morning, with GlaxoSmithKline Pharmaceuticals leading the charge—rising 7.4% to ₹2,992.80 as of 10:05 AM. The broader sector saw widespread buying, with gains seen across major names like Torrent Pharma, Alkem, and Divi’s Labs.
Torrent Pharmaceuticals rose 3.28% to ₹3,347.80, reacting to its Q4 earnings and mixed brokerage commentary. Nuvama retained its buy rating with a ₹3,760 target, citing strong India and US growth, while Nomura maintained a neutral stance with a ₹3,580 target, flagging a 4% PAT miss due to one-time litigation charges.
Gland Pharma was not part of the top gainers list as of 10:05 AM but remains in focus after its Q4FY25 results. According to Nomura, the company reported in-line sales but missed EBITDA and PAT estimates due to higher employee expenses. However, management’s FY26 revenue growth guidance of mid-teens (vs. earlier 9.5% estimate) was seen as a key positive. Nomura maintained a neutral rating with a target of ₹1,570.
Other key movers in the pharma pack included:
-
Alkem: ₹5,390.00 (+2.49%)
-
Divis Labs: ₹6,580.00 (+1.98%)
-
Lupin: ₹2,005.20 (+1.95%)
-
Sun Pharma: ₹1,735.90 (+1.65%)
-
Abbott India: ₹31,175.00 (+1.07%)
-
Mankind: ₹2,556.90 (+0.30%)
The overall momentum in the pharma sector is being supported by positive earnings, margin resilience, and increasing optimism around export-led demand recovery.
Disclaimer: This article is for informational purposes only and is based solely on publicly available data and provided inputs. It does not constitute investment advice. Always consult a qualified financial advisor before making investment decisions.
